Moderated by Scott Henry, Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research at ROTH Capital Partners, LLC, will conduct a fireside chat with Mr. Bagai, who will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx’s open label pivotal Phase III TIGeR- PaC study.
ROTH MKM Healthcare Opportunities Conference
Date: October 12, 2023Time: 11:30 AM Speaker: Shaun Bagai, CEO
Go to Renovo's website to register if interested
Why IMU is a multi multi bagger, page-16657
-
- There are more pages in this discussion • 8,896 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.001(1.79%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $757.1K | 13.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 2203877 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 244428 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |